Amgen (AMGN) is facing an antitrust lawsuit in the US filed by Sandoz, accusing Amgen of "extending and entrenching" the leading market position of its Enbrel medicine, also known as etanercept.
Sandoz said Monday that Amgen "blocked competition" from Enbrel biosimilars, including Erelzi from Sandoz, by illegally acquiring and using certain patent rights to entrench its market position.
Enbrel is approved in the US for patients with disabling inflammatory diseases and Sandoz said it received US FDA approval for Erelzi in 2016.
Apart from damages, Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block Enbrel's biosimilar competition and allow it to launch Erelzi, according to the statement.
Amgen did not immediately respond to a request for comment from MT Newswires.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。